Abstract
The BRAF V600E mutation aberrantly activates the mitogen-activated protein kinase (MAPK) pathway, subsequently resulting in uncontrolled cellular proliferation, survival, and dedifferentiation. Approximately 2% of patients with non–small cell lung cancer (NSCLC) have a BRAF V600E mutation. BRAF and MEK inhibitor combination therapy targets two kinases within the MAPK pathway. Encorafenib (Braftovi) and binimetinib (Mektovi) are potent oral inhibitors of BRAF and MEK, respectively. With the recent US Food and Drug Administration approval of encorafenib plus binimetinib, adult patients with BRAF V600E–mutated metastatic NSCLC have an additional treatment option. In the phase II PHAROS study, encorafenib plus binimetinib achieved the primary endpoint of objective response rate by independent review committee and exhibited a manageable safety profile in this patient population. This article provides an overview of the efficacy and safety of encorafenib plus binimetinib and uses a fictional patient case to illustrate the role of advanced practice providers in providing individualized patient care and identifying and managing adverse reactions.
References
Abdayem, P. A., & Planchard, D. (2022). Ongoing process in BRAF-mutated non-small cell lung cancer. Clinical Advances in Hematology & Oncology, 20(11), 662–672.
Array BioPharma Inc. (2018a). Braftovi (encorafenib) package insert. https://www.accessdata.fda.gov/spl/data/c2eedf4c-59b6-43ed-9820-a5621fa3e18f/c2eedf4c-59b6-43ed-9820-a5621fa3e18f.xml
Array BioPharma Inc. (2018b). Mektovi (binimetinib) package insert. https://www.accessdata.fda.gov/spl/data/4e0f2551-01a9-46c6-8019-bd5535c09ee6/4e0f2551-01a9-46c6-8019-bd5535c09ee6.xml
AstraZeneca Pharmaceuticals LP. (2003). Crestor (rosuvastatin) package insert. https://www.accessdata.fda.gov/spl/data/18053149-18b6-427b-b740-5541f6ed2000/18053149-18b6-427b-b740-5541f6ed2000.xml
Augustyn, K., Joseph, J., Patel, A. B., Razmandi, A., Ali, A. N., & Tawbi, H. A. (2023). Treatment expereince with encorafenib plus binimetinib for BRAF V600-mutant metastatic melanoma: Management insights for clinical practice. Melanoma Research, 33(5), 406–416. https://doi.org/10.1097/CMR.0000000000000891
Baik, C., Cheng, M. L., Dietrich, M., Gray, J. E., & Karim, N. A. (2024). A practical review of encorafenib and binimetinib therapy management in patients with BRAF V600E-mutant metastatic non-small cell lung cancer. Advances in Therapy, 41(7), 2586–2605. https://doi.org/10.1007/s12325-024-02839-4
Baik, C. S., Myall, N. J., & Wakelee, H. A. (2017). Targeting BRAF-mutant non-small cell lung cancer: From molecular profiling to rationally designed therapy. The Oncologist, 22(7), 786–796. https://doi.org/10.1634/theoncologist.2016-0458
Barlesi, F., Mazieres, J., Merlio, J., Debieurve, D., Mosser, J., Lena, H., & Ouaik, L. (2016). Routine molecular profiling of cancer: results of a one-year nationwide program at the French Cooperative Thoracic Intergroup (IFCT) for advanced non-small cell lung cancer (NSCLC) patients. The Lancet, 387(10026), 1415–1426. https://doi.org/10.1016/S0140-6736(16)00004-0
Bhandari, N. R., Hess, L. M., He, D., & Peterson, P. (2023). Biomarker testing, treatment, and outcomes in patients with advanced/metastatic non-small cell lung cancer using a real-world database. Journal of the National Comprehensive Cancer Network, 21(9), 934–944 e931. https://doi.org/10.6004/jnccn.2023.7039
Cardarella, S., Ogino, A., Nishino, M., Butaney, M., Shen, J., Lydon, C.,…Janne, P. A. (2013). Clinical, pathologic, and biologic features associated with BRAF mutations in non-small cell lung cancer. Clinical Cancer Research, 19(16), 4532–4540. https://doi.org/10.1158/1078-0432.CCR-13-0657
Dagogo-Jack, I., Martinez, P., Yeap, B. Y., Ambrogio, C., Ferris, L. A., Lydon, C.,…Awad, M. M. (2019). Impact of BRAF mutation class on disease characteristics and clinical outcomes in BRAF-mutant lung cancer. Clinical Cancer Research, 25(1), 158–165. https://doi.org/10.1158/1078-0432.CCR-18-2062
Dudnik, E., Peled, N., Nechushtan, H., Wollner, M., Onn, A., Agbarya, A.,…Israel Lung Cancer Group. (2018). BRAF mutant lung cancer: Programmed death ligand 1 expression, tumor mutational burden, microsatellite instability status, and response to immune check-point inhibitors. Journal of Thoracic Oncology, 13(8), 1128–1137. https://doi.org/10.1016/j.jtho.2018.04.024
Dummer, R., Ascierto, P. A., Gogas, H. J., Arance, A., Mandala, M., Liszkay, G.,…Flaherty, K. T. (2018). Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma (COLUMBUS): A multicentre, open-label, randomised phase 3 trial. Lancet Oncology, 19(5), 603–615. https://doi.org/10.1016/S1470-2045(18)30142-6
Gogas, H. J., Flaherty, K. T., Dummer, R., Ascierto, P. A., Arance, A., Mandala, M.,…Robert, C. (2019). Adverse events associated with encorafenib plus binimetinib in the COLUMBUS study: Incidence, course and management. European Journal of Cancer, 119, 97–106. https://doi.org/10.1016/j.ejca.2019.07.016
Guisier, F., Dubos-Arvis, C., Vinas, F., Doubre, H., Ricordel, C., Ropert, S.,…Bylicki, O. (2020). Efficacy and safety of anti-PD-1 immunotherapy in patients with advanced NSCLC with BRAF, HER2, or MET mutations or RET translocation: GFPC 01-2018. Journal of Thoracic Oncology, 15(4), 628–636. https://doi.org/10.1016/j.jtho.2019.12.129
Hendriks, L. E., Kerr, K. M., Menis, J., Mok, T. S., Nestle, U., Passaro, A.,…Reck, M. (2023). Oncogene-addicted metastatic non-small-cell lung cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Annals of Oncology, 34(4), 339–357. https://doi.org/10.1016/j.annonc.2022.12.009
Hoffman, P., Roden, A. C., Chung, J. H., & Planchard, D. (2023). IASLC atlas of molecular testing for targeted therapy in lung cancer.
Hsu, K. H., Tseng, J. S., Yang, T. Y., Chen, K. C., Su, K. Y., Yu, S. L.,…Chang, G. C. (2022). PD-L1 strong expressions affect the clinical outcomes of osimertinib in treatment naive advanced EGFR-mutant non-small cell lung cancer patients. Science Reports, 12(1), 9753. https://doi.org/10.1038/s41598-022-13102-7
Janssen Pharmaceuticals, Inc. (2024). Sporanox (itraconazole) package insert. https://www.accessdata.fda.gov/spl/data/115d4f3d-303d-e42c-e063-6294a90a7d9e/115d4f3d-303d-e42c-e063-6294a90a7d9e.xml
Koelblinger, P., Thuerigen, O., & Dummer, R. (2018). Development of encorafenib for BRAF-mutated advanced melanoma. Current Opinion in Oncology, 30(2), 125–133. https://doi.org/10.1097/CCO.0000000000000426
Marchetti, A., Felicioni, L., Malatesta, S., Grazia Sciarrotta, M., Guetti, L., Chella, A.,…Buttitta, F. (2011). Clinical features and outcome of patients with non-small-cell lung cancer harboring BRAF mutations. Journal of Clinical Oncology, 29(26), 3574–3579. https://doi.org/10.1200/JCO.2011.35.9638
Mazieres, J., Cropet, C., Montane, L., Barlesi, F., Souquet, P. J., Quantin, X.,…Blay, J. Y. (2020). Vemurafenib in non-small-cell lung cancer patients with BRAF(V600) and BRAF(nonV600) mutations. Annals of Oncology, 31(2), 289–294. https://doi.org/10.1016/j.annonc.2019.10.022
Mazieres, J., Drilon, A., Lusque, A., Mhanna, L., Cortot, A. B., Mezquita, L.,…Gautschi, O. (2019). Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: Results from the IMMUNOTARGET registry. Annals of Oncology, 30(8), 1321–1328. https://doi.org/10.1093/annonc/mdz167
Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Non-Small Cell Lung Cancer V.3.2024. © National Comprehensive Cancer Network, Inc. 2024. All rights reserved. Accessed [March 21, 2024]. To view the most recent complete version of the guideline, go online to NCCN.org. NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way.
Negrao, M. V., Skoulidis, F., Montesion, M., Schulze, K., Bara, I., Shen, V.,…Heymach, J. V. (2021). Oncogene-specific differences in tumor mutational burden, PD-L1 expression, and outcomes from immunotherapy in non-small cell lung cancer. Journal for Immunotherapy Cancer, 9(8), e002891. https://doi.org/10.1136/jitc-2021-002891
Novartis Pharmaceuticals Corporation. (2013a). Mekinist (trametinib) package insert. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/204114s025lbl.pdf
Novartis Pharmaceuticals Corporation. (2013b). Tafinlar (dabrafenib) package insert. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/202806s025lbl.pdf
Ottaviano, M., Giunta, E. F., Tortora, M., Curvietto, M., Attademo, L., Bosso, D.,…Simeone, E. (2021). BRAF gene and melanoma: Back to the future. International Journal of Molecular Sciences, 22(7), 3474. https://doi.org/10.3390/ijms22073474
Owsley, J., Stein, M. K., Porter, J., In, G. K., Salem, M., O’Day, S.,…VanderWalde, A. (2021). Prevalence of class I-III BRAF mutations among 114,662 cancer patients in a large genomic database. Experimental Biology and Medicine, 246(1), 31–39. https://doi.org/10.1177/1535370220959657
Pai-Scherf, L., Blumenthal, G. M., Li, H., Subramaniam, S., Mishra-Kalyani, P. S., He, K.,…Pazdur, R. (2017). FDA approval summary: Pembrolizumab for treatment of metastatic non-small cell lung cancer: first-line therapy and beyond. The Oncologist, 22(11), 1392–1399. https://doi.org/10.1634/theoncologist.2017-0078
Planchard, D., Besse, B., Groen, H. J. M., Hashemi, S. M. S., Mazieres, J., Kim, T. M.,…Johnson, B. E. (2022). Phase 2 study of dabrafenib plus trametinib in patients with BRAF V600E-mutant metastatic NSCLC: Updated 5-year survival rates and genomic analysis. Journal of Thoracic Oncology, 17(1), 103–115. https://doi.org/10.1016/j.jtho.2021.08.011
Planchard, D., Besse, B., Groen, H. J. M., Souquet, P. J., Quoix, E., Baik, C. S.,…Johnson, B. E. (2016b). Dabrafenib plus trametinib in patients with previously treated BRAF(V600E)-mutant metastatic non-small cell lung cancer: An open-label, multicentre phase 2 trial. The Lancet Oncology, 17(7), 984–993. https://doi.org/10.1016/S1470-2045(16)30146-2
Planchard, D., Kim, T. M., Mazieres, J., Quoix, E., Riely, G., Barlesi, F.,…Johnson, B. E. (2016a). Dabrafenib in patients with BRAF(V600E)-positive advanced non-small-cell lung cancer: A single-arm, multicentre, open-label, phase 2 trial. The Lancet Oncology, 17(5), 642–650. https://doi.org/10.1016/S1470-2045(16)00077-2
Planchard, D., Smit, E. F., Groen, H. J. M., Mazieres, J., Besse, B., Helland, A.,…Johnson, B. E. (2017). Dabrafenib plus trametinib in patients with previously untreated BRAF(V600E)-mutant metastatic non-small-cell lung cancer: An open-label, phase 2 trial. The Lancet Oncology, 18(10), 1307–1316. https://doi.org/10.1016/S1470-2045(17)30679-4
RedHill Biopharma Ltd. (2024). Aemcolo (rifamycin) package insert. https://www.accessdata.fda.gov/spl/data/9377a845-abf1-4c32-84e6-51ee3473c9d2/9377a845-abf1-4c32-84e6-51ee3473c9d2.xml
Riely, G. J., Smit, E. F., Ahn, M. J., Felip, E., Ramalingam, S. S., Tsao, A.,…Johnson, B. E. (2023). Phase II, open-label study of encorafenib plus binimetinib in patients with BRAF(V600)-mutant metastatic non-small-cell lung cancer. Journal of Clinical Oncology, 41(21), 3700–3711. https://doi.org/10.1200/JCO.23.00774
Sheikine, Y., Pavlick, D., Klempner, S. J., Trabucco, S. E., Chung, J. H., Rosenzweig, M.,…Peled, N. (2018). BRAF in lung cancers: Analysis of patient cases reveals recurrent BRAF mutations, fusions, kinase duplications, and concurrent alterations. JCO Precision Oncology, 2, PO.17.00172. https://doi.org/10.1200/PO.17.00172
Smiech, M., Leszczynski, P., Kono, H., Wardell, C., & Taniguchi, H. (2020). Emerging BRAF mutations in cancer progression and their possible effects on transcriptional networks. Genes (Basel), 11(11), 1342. https://doi.org/10.3390/genes11111342
Subbiah, V., Baik, C., & Kirkwood, J. M. (2020). Clinical development of BRAF plus MEK inhibitor combinations. Trends in Cancer, 6(9), 797–810. https://doi.org/10.1016/j.trecan.2020.05.009
Tran, B., & Cohen, M. S. (2020). The discovery and development of binimetinib for the treatment of melanoma. Expert Opinion on Drug Discovery, 15(7), 745–754. https://doi.org/10.1080/17460441.2020.1746265
US Food and Drug Administration. (2023a). Drug development and drug interactions | table of substrates, inhibitors, and inducers. https://www.fda.gov/drugs/drug-interactions-labeling/drug-development-and-drug-interactions-table-substrates-inhibitors-and-inducers#table2-2
US Food and Drug Administration. (2023b). FDA approves encorafenib with binimetinib for metastatic non-small cell lung cancer with a BRAF V600E mutation. https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-encorafenib-binimetinib-metastatic-non-small-cell-lung-cancer-braf-v600e-mutation
Waterhouse, D. M., Tseng, W. Y., Espirito, J. L., & Robert, N. J. (2021). Understanding contemporary molecular biomarker testing rates and trends for metastatic NSCLC among community oncologists. Clinical Lung Cancer, 22(6), e901–e910. https://doi.org/10.1016/j.cllc.2021.05.006
Yaeger, R., & Corcoran, R. B. (2019). Targeting alterations in the RAF-MEK pathway. Cancer Discovery, 9(3), 329–341. https://doi.org/10.1158/2159-8290.CD-18-1321
